Modality
ADC
MOA
JAK1i
Target
BCMA
Pathway
Neuroinflam
HSFabry
Development Pipeline
Preclinical
Mar 2017
→ Jul 2029
PreclinicalCurrent
NCT03704716
1,032 pts·HS
2017-03→2026-10·Completed
NCT08700864
1,695 pts·HS
2021-06→2029-07·Completed
2,727 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-187mo awayInterim· HS
2029-07-283.3y awayInterim· HS
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2026-10-18 · 7mo away
HS
Interim
2029-07-28 · 3.3y away
HS
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03704716 | Preclinical | HS | Completed | 1032 | DAS28 |
| NCT08700864 | Preclinical | HS | Completed | 1695 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |